-+ 0.00%
-+ 0.00%
-+ 0.00%

ARMATA PHARMACEUTICALS - FDA DEFERS PEDIATRIC STUDIES FOR AP-SA02 UNTIL ADULT PHASE 3 DATA GENERATED

Reuters·07/13/2026 11:00:01

Please log in to view news